HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Povidone iodine/hydrogen peroxide chronic use studies needed for antigingival claims.

This article was originally published in The Rose Sheet

Executive Summary

POVIDONE IODINE/HYDROGEN PEROXIDE RINSE CHRONIC USE STUDIES NEEDED to support antigingival claims for the product, FDA's Dental Products Panel Plaque Subcommittee agreed at a May 8-9 meeting in Bethesda, Md. The subcommittee conclusion followed a presentation by Gunning Point Consulting Group Director Samuel Trotz, PhD, on behalf of Perimed, the manufacturer of Perimed oral rinse.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel